Ethnic difference in contribution of alleles of the interleukin‐1 receptor antagonist gene to predisposition to osteoporosis

Background:  The interleukin‐1 receptor antagonist (IL‐1RA) plays an important role in bone metabolism, and molecular defects are implicated in the pathogenesis of osteoporosis. Studies performed in Caucasian populations have demonstrated an association between allelic variants of the IL‐1RA gene and bone mineral density (BMD).

[1]  D. Crossman,et al.  Interleukin-1 Receptor Antagonist Expression in Human Endothelial Cells and Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[2]  E. Eriksen,et al.  Osteoporotic Fractures Are Associated with an 86‐Base Pair Repeat Polymorphism in the Interleukin‐1‐Receptor Antagonist Gene But Not with Polymorphisms in the Interleukin‐1β Gene , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  T. Nakajima,et al.  Ethnic Difference in Contribution of Sp1 Site Variation of COLIA1 Gene in Genetic Predisposition to Osteoporosis , 1999, Calcified Tissue International.

[4]  T. Spector,et al.  Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine. , 1998, Bone.

[5]  M. Emi,et al.  Isolation and mapping of a polymorphic CA repeat sequence at the human interleukin 6 locus , 1998, Journal of Human Genetics.

[6]  S. Grant,et al.  Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I α 1 gene , 1996, Nature Genetics.

[7]  Y. Ouchi,et al.  Association of bone mineral density with polymorphism of the estrogen receptor gene , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  T. Spector,et al.  Influence of vitamin D receptor genotype on bone mineral density in postmenopausal women: a twin study in Britain , 1995, BMJ.

[9]  D. Grennan,et al.  Cytokine production by normal human monocytes: inter‐subject variation and relationship to an IL‐1 receptor antagonist (IL‐1Ra) gene polymorphism , 1995, Clinical and experimental immunology.

[10]  A. Steinkasserer,et al.  Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. , 1994, Journal of immunology.

[11]  J. Eisman,et al.  Prediction of bone density from vitamin D receptor alleles , 1994, Nature.

[12]  G. Passeri,et al.  Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. , 1993, Endocrinology.

[13]  A. Blakemore,et al.  Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat , 1993, Human Genetics.

[14]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[15]  T. Linkhart,et al.  Interleukin-1 stimulates release of insulin-like growth factor-I from neonatal mouse calvaria by a prostaglandin synthesis-dependent mechanism. , 1992, Endocrinology.

[16]  D. Sheer,et al.  Cloning and chromosome mapping of the human interleukin-1 receptor antagonist gene. , 1992, Cytokine.

[17]  S. Haskill,et al.  cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Hopper,et al.  Reduced bone mass in daughters of women with osteoporosis. , 1989, The New England journal of medicine.

[19]  J. Hopper,et al.  Genetic determinants of bone mass in adults. A twin study. , 1987, The Journal of clinical investigation.